A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

Summary

* 1\. There is no standard treatment option for non-clear cell renal cell carcinoma (RCC). * 2\. Patients with non-clear cell RCC is strongly assumed to have benefit from anti-VEGF treatment. * 3\. There is no trial of axitinib for non-clear cell RCC. * 4\. Axitinib is expected to show more potent efficacy over sorafenib or sunitinib in renal cell carcinoma.

Timeline

Start

2013-02

Primary completion

2015-06

Completion

2016-12

Publications

• Background Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4.

Drugs

Indications